Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Paul Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the sale, the insider directly owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. The trade was a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Neumora Therapeutics Stock Down 3.1%

NASDAQ:NMRA traded down $0.11 during trading hours on Thursday, reaching $3.48. The company’s stock had a trading volume of 1,491,798 shares, compared to its average volume of 2,331,130. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The company has a market cap of $581.47 million, a price-to-earnings ratio of -2.37 and a beta of 3.20. Neumora Therapeutics, Inc. has a one year low of $0.61 and a one year high of $3.65. The business’s 50-day moving average is $2.15 and its 200-day moving average is $2.05.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NMRA. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Stifel Nicolaus upped their price objective on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Guggenheim upgraded shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Monday, October 27th. Finally, Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.13.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Siren L.L.C. lifted its holdings in shares of Neumora Therapeutics by 44.3% during the fourth quarter. Siren L.L.C. now owns 6,288,783 shares of the company’s stock valued at $11,257,000 after acquiring an additional 1,930,500 shares during the period. Millennium Management LLC increased its position in shares of Neumora Therapeutics by 80.1% during the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after purchasing an additional 1,608,266 shares in the last quarter. Ikarian Capital LLC lifted its holdings in Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after purchasing an additional 1,265,910 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Neumora Therapeutics during the 3rd quarter valued at about $1,512,000. Finally, Marshall Wace LLP acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $1,045,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.